Doctors conclude temsirolimus is effective new treatment for advanced renal cell...( The results of a phase III randomized...),Health

The results of a phase III, randomized clinical study involving patients with advanced renal cell carcinoma and poor prognostic features show temsirolimus improved overall survival when compared to the current treatment for this stage of disease. The study, led by Gary R. Hudes, M.D., director of the Genitourinary Malignancies Program at Fox Chase Cancer Center, is published in the May 31 issue of the New England Journal of Medicine.

A total of 626 patients with renal cell carcinoma (RCC) were enrolled in the study and received one of three treatments a new drug called temsirolimus, an older drug called interferon, or both the new and old drugs together. The patients who received temsirolimus alone survived longer than those who received interferon, the usual or standard treatment for this disease.

"This is the first study to show that a new drug can improve overall survival for patients with metastatic renal cell cancer," said Hudes.

Patients who received both drugs - temsirolimus and interferon - did not appear to live longer than those given interferon. Hudes said this finding could be explained by the lower dose of temsirolimus given to patients who received the combination treatment.

Renal cell carcinoma (RCC) is the most common type of kidney cancer. Approximately 90 percent of the 51,190 new cases of kidney cancer diagnosed this year will be RCC. Although many patients with kidney cancer are cured by surgery that removes the tumor, approximately 35 percent of patients will experience a recurrence of their cancer or will have spread (metastasis) of their cancer to other organs.

"For these patients, the goal of treatment is to prevent further spread and growth of the cancer, and ideally, to reduce that amount of cancer," Hudes said. "Until recently, physicians lacked effective drugs to control the disease."

In the current study, the greatest increase in median survival was observed i
'"/>

Contact: Karen Mallet
karen.mallet@fccc.edu
215-728-2700
Fox Chase Cancer Center
30-May-2007